STOCK TITAN

[Form 4] MiMedx Group, Inc Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

MiMedx Group director Dorothy E. Puhy received an annual restricted stock grant of 28,609 shares on June 18, 2025, at a price of $6.47 per share. Following this transaction, Puhy's direct ownership increased to 57,597 shares.

Key transaction details:

  • Transaction type: Non-derivative securities acquisition
  • Grant type: Annual restricted stock award to non-employee director
  • Vesting terms: Earlier of 12 months or next annual shareholder meeting
  • Transaction exempt under Rule 16b-3

This Form 4 filing, signed by William F. Hulse as attorney-in-fact, represents standard annual director compensation in the form of equity, demonstrating continued alignment between director and shareholder interests.

La direttrice del gruppo MiMedx, Dorothy E. Puhy, ha ricevuto una concessione annuale di azioni vincolate pari a 28.609 azioni il 18 giugno 2025, al prezzo di 6,47 $ per azione. Dopo questa operazione, la proprietà diretta di Puhy è aumentata a 57.597 azioni.

Dettagli principali della transazione:

  • Tipo di transazione: acquisizione di titoli non derivati
  • Tipo di concessione: premio annuale di azioni vincolate per direttore non dipendente
  • Termini di maturazione: il prima tra 12 mesi o la prossima assemblea annuale degli azionisti
  • Transazione esente ai sensi della Regola 16b-3

Questa dichiarazione Form 4, firmata da William F. Hulse in qualità di procuratore, rappresenta una normale compensazione annuale per il direttore sotto forma di equity, dimostrando un continuo allineamento tra gli interessi del direttore e quelli degli azionisti.

La directora del grupo MiMedx, Dorothy E. Puhy, recibió una concesión anual de acciones restringidas por 28.609 acciones el 18 de junio de 2025, a un precio de $6.47 por acción. Tras esta operación, la propiedad directa de Puhy aumentó a 57.597 acciones.

Detalles clave de la transacción:

  • Tipo de transacción: adquisición de valores no derivados
  • Tipo de concesión: premio anual de acciones restringidas para director no empleado
  • Términos de adquisición: el primero entre 12 meses o la próxima junta anual de accionistas
  • Transacción exenta bajo la Regla 16b-3

Esta presentación del Formulario 4, firmada por William F. Hulse como apoderado, representa una compensación anual estándar para directores en forma de acciones, demostrando la continua alineación entre los intereses del director y los accionistas.

MiMedx 그룹 이사 Dorothy E. Puhy는 2025년 6월 18일에 28,609주의 연간 제한 주식 보조금을 주당 $6.47의 가격으로 받았습니다. 이 거래 이후 Puhy의 직접 소유 주식은 57,597주로 증가했습니다.

주요 거래 세부사항:

  • 거래 유형: 비파생 증권 취득
  • 보조금 유형: 비임원 이사에 대한 연간 제한 주식 수여
  • 베스팅 조건: 12개월 또는 다음 연례 주주총회 중 빠른 시기
  • 거래는 Rule 16b-3에 따라 면제됨

William F. Hulse가 대리인으로 서명한 이 Form 4 제출은 주식 형태의 표준 연간 이사 보상을 나타내며, 이사와 주주 간의 지속적인 이해관계 일치를 보여줍니다.

La directrice du groupe MiMedx, Dorothy E. Puhy, a reçu une attribution annuelle d’actions restreintes de 28 609 actions le 18 juin 2025, au prix de 6,47 $ par action. Suite à cette opération, la détention directe de Puhy est passée à 57 597 actions.

Détails clés de la transaction :

  • Type de transaction : acquisition de titres non dérivés
  • Type d’attribution : attribution annuelle d’actions restreintes à un administrateur non salarié
  • Modalités d’acquisition : la première échéance entre 12 mois ou la prochaine assemblée annuelle des actionnaires
  • Transaction exonérée en vertu de la règle 16b-3

Ce dépôt du formulaire 4, signé par William F. Hulse en tant que mandataire, représente une rémunération annuelle standard des administrateurs sous forme d’actions, démontrant l’alignement continu des intérêts entre l’administrateur et les actionnaires.

Die Direktorin der MiMedx-Gruppe, Dorothy E. Puhy, erhielt am 18. Juni 2025 eine jährliche Zuteilung von 28.609 eingeschränkten Aktien zu einem Preis von 6,47 $ pro Aktie. Nach dieser Transaktion erhöhte sich Puhys Direktbesitz auf 57.597 Aktien.

Wichtige Transaktionsdetails:

  • Transaktionstyp: Erwerb von nicht-derivativen Wertpapieren
  • Zuteilungstyp: jährliche eingeschränkte Aktienzuteilung an nicht-geschäftsführendes Vorstandsmitglied
  • Vesting-Bedingungen: früher von 12 Monaten oder der nächsten jährlichen Hauptversammlung
  • Transaktion gemäß Regel 16b-3 ausgenommen

Diese Form 4 Einreichung, unterzeichnet von William F. Hulse als Bevollmächtigter, stellt eine standardmäßige jährliche Vergütung für Direktoren in Form von Eigenkapital dar und zeigt die fortgesetzte Übereinstimmung der Interessen von Direktor und Aktionären.

Positive
  • None.
Negative
  • None.

La direttrice del gruppo MiMedx, Dorothy E. Puhy, ha ricevuto una concessione annuale di azioni vincolate pari a 28.609 azioni il 18 giugno 2025, al prezzo di 6,47 $ per azione. Dopo questa operazione, la proprietà diretta di Puhy è aumentata a 57.597 azioni.

Dettagli principali della transazione:

  • Tipo di transazione: acquisizione di titoli non derivati
  • Tipo di concessione: premio annuale di azioni vincolate per direttore non dipendente
  • Termini di maturazione: il prima tra 12 mesi o la prossima assemblea annuale degli azionisti
  • Transazione esente ai sensi della Regola 16b-3

Questa dichiarazione Form 4, firmata da William F. Hulse in qualità di procuratore, rappresenta una normale compensazione annuale per il direttore sotto forma di equity, dimostrando un continuo allineamento tra gli interessi del direttore e quelli degli azionisti.

La directora del grupo MiMedx, Dorothy E. Puhy, recibió una concesión anual de acciones restringidas por 28.609 acciones el 18 de junio de 2025, a un precio de $6.47 por acción. Tras esta operación, la propiedad directa de Puhy aumentó a 57.597 acciones.

Detalles clave de la transacción:

  • Tipo de transacción: adquisición de valores no derivados
  • Tipo de concesión: premio anual de acciones restringidas para director no empleado
  • Términos de adquisición: el primero entre 12 meses o la próxima junta anual de accionistas
  • Transacción exenta bajo la Regla 16b-3

Esta presentación del Formulario 4, firmada por William F. Hulse como apoderado, representa una compensación anual estándar para directores en forma de acciones, demostrando la continua alineación entre los intereses del director y los accionistas.

MiMedx 그룹 이사 Dorothy E. Puhy는 2025년 6월 18일에 28,609주의 연간 제한 주식 보조금을 주당 $6.47의 가격으로 받았습니다. 이 거래 이후 Puhy의 직접 소유 주식은 57,597주로 증가했습니다.

주요 거래 세부사항:

  • 거래 유형: 비파생 증권 취득
  • 보조금 유형: 비임원 이사에 대한 연간 제한 주식 수여
  • 베스팅 조건: 12개월 또는 다음 연례 주주총회 중 빠른 시기
  • 거래는 Rule 16b-3에 따라 면제됨

William F. Hulse가 대리인으로 서명한 이 Form 4 제출은 주식 형태의 표준 연간 이사 보상을 나타내며, 이사와 주주 간의 지속적인 이해관계 일치를 보여줍니다.

La directrice du groupe MiMedx, Dorothy E. Puhy, a reçu une attribution annuelle d’actions restreintes de 28 609 actions le 18 juin 2025, au prix de 6,47 $ par action. Suite à cette opération, la détention directe de Puhy est passée à 57 597 actions.

Détails clés de la transaction :

  • Type de transaction : acquisition de titres non dérivés
  • Type d’attribution : attribution annuelle d’actions restreintes à un administrateur non salarié
  • Modalités d’acquisition : la première échéance entre 12 mois ou la prochaine assemblée annuelle des actionnaires
  • Transaction exonérée en vertu de la règle 16b-3

Ce dépôt du formulaire 4, signé par William F. Hulse en tant que mandataire, représente une rémunération annuelle standard des administrateurs sous forme d’actions, démontrant l’alignement continu des intérêts entre l’administrateur et les actionnaires.

Die Direktorin der MiMedx-Gruppe, Dorothy E. Puhy, erhielt am 18. Juni 2025 eine jährliche Zuteilung von 28.609 eingeschränkten Aktien zu einem Preis von 6,47 $ pro Aktie. Nach dieser Transaktion erhöhte sich Puhys Direktbesitz auf 57.597 Aktien.

Wichtige Transaktionsdetails:

  • Transaktionstyp: Erwerb von nicht-derivativen Wertpapieren
  • Zuteilungstyp: jährliche eingeschränkte Aktienzuteilung an nicht-geschäftsführendes Vorstandsmitglied
  • Vesting-Bedingungen: früher von 12 Monaten oder der nächsten jährlichen Hauptversammlung
  • Transaktion gemäß Regel 16b-3 ausgenommen

Diese Form 4 Einreichung, unterzeichnet von William F. Hulse als Bevollmächtigter, stellt eine standardmäßige jährliche Vergütung für Direktoren in Form von Eigenkapital dar und zeigt die fortgesetzte Übereinstimmung der Interessen von Direktor und Aktionären.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
PUHY DOROTHY E

(Last) (First) (Middle)
1775 WEST OAK COMMONS CT NE

(Street)
MARIETTA GA 30062

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MIMEDX GROUP, INC. [ MDXG ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/18/2025 A 28,609(1) A $6.47 57,597 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders
Remarks:
/s/ William F. Hulse as attorney-in-fact Dorothy Puhy 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many MDXG shares did Director Dorothy Puhy acquire on June 18, 2025?

Director Dorothy Puhy acquired 28,609 shares of MDXG common stock on June 18, 2025, at a price of $6.47 per share. This was an annual restricted stock grant to non-employee directors.

What is the vesting period for MDXG's director stock grants in 2025?

According to the filing, the restricted stock grant vests upon the earlier of 12 months or the next annual meeting of shareholders. This grant was made under Rule 16b-3 exemption for non-employee directors.

How many MDXG shares does Dorothy Puhy own after the June 2025 stock grant?

Following the reported transaction, Dorothy Puhy beneficially owns 57,597 shares of MDXG common stock directly (indicated as ownership form 'D' in the filing).

Did MDXG Director Dorothy Puhy purchase these shares on the open market?

No, these shares were not purchased on the open market. The filing indicates this was an annual restricted stock grant (transaction code 'A') to non-employee directors, exempt under Rule 16b-3.
Mimedx Group Inc

NASDAQ:MDXG

MDXG Rankings

MDXG Latest News

MDXG Latest SEC Filings

MDXG Stock Data

877.35M
144.97M
2.72%
69.9%
2.78%
Biotechnology
Surgical & Medical Instruments & Apparatus
Link
United States
MARIETTA